Towards the Development of a Broadly Protective Group A Streptococcal Vaccine Based on the Lipid-Core Peptide System
C. Olive, P. M. Moyle and I. Toth
Affiliation: The Queensland Institute of Medical Research,PO Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia.
Preclinical studies carried out over the last seven years by our group have focused on the development of a group A streptococcal (GAS) vaccine based on the antiphagocytic bacterial surface M protein using the Lipid-Core Peptide (LCP) system. This synthetic peptide vaccine delivery system has several advantages over other delivery systems including its self-adjuvanting properties and the ability to incorporate multiple peptide epitopes into a single vaccine. This review describes various vaccine delivery strategies including the LCP system, highlighting its functional properties and applications in vaccine research using data obtained from various LCP-based GAS vaccine candidates evaluated in murine models.
Keywords: Synthetic peptide vaccines, Lipid-Core Peptide system, multiepitope vaccines, self-adjuvanting, group A streptococcus, M protein
Rights & PermissionsPrintExport